Abstract 20P
Background
DNA repair deficiency is a common feature of cancer. Homologous recombination (HR) and nucleotide excision repair (NER) are two most frequently disabled DNA repair pathways in solid tumors. HR deficient breast, ovarian, pancreatic and prostate cancers respond well to platinum chemotherapy and PARP inhibitors. However, frequency of DNA repair pathway deficiency in gastric and esophageal adenocarcinoma (GEA) still lacks diagnostic and functional validation. Furthermore, whether DNA repair deficient GEA have enhanced responsiveness to platinum chemotherapy and sensitivity to PARP inhibitors is not well characterized.
Methods
Using whole exome and genome sequencing data, we measured various HR deficiency-associated mutational signatures in patient specimen of gastric, esophageal and colorectal cancer specimens and gastric cancer cell lines. Gold-standard immunofluorescence assays were used to confirm HR and NER deficiency in cancer cell lines. Relationship between PARP inhibitor treatment and tumor response was evaluated in patients with gastric cancer. Drug sensitivity was determined using standard in vitro cell culture assays. Single-cell RNA-sequencing was done to evaluate gastric cancer response to commonly used chemotherapeutics.
Results
We found that a significant subset of GEA, but very few colorectal tumors, show evidence of HR deficiency by mutational signature analysis (HRD score). Gastric cancer cell lines with high HRD mutational signature scores demonstrated functional HR deficiency by RAD51 assay and increased sensitivity to platinum and PARP inhibitors. A gastric cancer cell line with strong sensitivity to cisplatin showed HR proficiency but exhibited NER deficiency by DDB2 proteo-probe assay. Single-cell RNA-sequencing revealed that, in addition to inducing general apoptosis, cisplatin treatment triggered ferroptosis in a NER-deficient gastric cancer, which may explain the outlier sensitivity.
Conclusions
A subset of upper gastrointestinal tumors have genomic features of HR and NER deficiency and therefore may be more likely to benefit from platinum chemotherapy and PARP inhibition.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Research and Technology Innovation Fund (KTIA_NAP_13-2014-0021 and 2017-1.2.1-NKP-2017-00002), Breast Cancer Research Foundation (BCRF-20-159), Kræftens Bekæmpelse (R281-A16566), Degregorio Family Foundation, AGA Augustyn Award in Digestive Diseases.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2P - SOT102, a novel CLDN18.2-targeting antibody-drug conjugate for gastric and pancreatic cancer with a wide range of the tumor target expression
Presenter: Radek Spisek
Session: Cocktail & Poster Display session
Resources:
Abstract
3P - Correlation between antibody-drug conjugate (ADC) targetable antigen expression and occurrence of interstitial lung disease (ILD)
Presenter: Solange Peters
Session: Cocktail & Poster Display session
Resources:
Abstract
4P - Optimizing utilization of antibody-drug conjugates in NSCLC by identification of subsets using RNA sequencing
Presenter: Edwin Lin
Session: Cocktail & Poster Display session
Resources:
Abstract
5P - Tisotumab vedotin (TV) dose schedule optimization in non-cervical populations
Presenter: Jenna Voellinger
Session: Cocktail & Poster Display session
Resources:
Abstract
6P - RC48-ADC for metastatic salivary duct carcinoma with HER2 expression: A single-center retrospective study
Presenter: jun Cao
Session: Cocktail & Poster Display session
Resources:
Abstract
7P - Global ring study determining reproducibility & comparability of CLDN18 testing assays in gastric cancer
Presenter: Bharat Jasani
Session: Cocktail & Poster Display session
Resources:
Abstract
8P - Targeting antiapoptotic Bcl-2 proteins with highly specific BH3 mimetics in solid tumors
Presenter: Benjamin Sobol
Session: Cocktail & Poster Display session
Resources:
Abstract
9P - An in vivo model for therapeutic antibody efficacy evaluation: The chicken embryo’s CAM-based assay
Presenter: Yan Wang
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - Successful transfer and prolonged persistence of engineered lymphocytes with T-cell receptor targeting NY-ESO-1
Presenter: Johnathan Arnon
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - CRISPR/Cas9-induced knock-out of DGKαζ in TAG-72 CAR-T cells improves function and persistence in ovarian cancer
Presenter: Vera Evtimov
Session: Cocktail & Poster Display session
Resources:
Abstract